Drugs in Dev.
Pulmonary/Respiratory Diseases
Phase II/ Phase III
Australia 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Remestemcel-L
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : $90.0 million
Deal Type : Financing
Details : A significant portion of the net proceeds will be used to scale-up manufacturing of remestemcel-L for the treatment of critically ill patients suffering with diseases caused by cytokine release syndromes associated with high mortality, particularly COVID...
Product Name : Ryoncil
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
May 13, 2020
Lead Product(s) : Remestemcel-L
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : $90.0 million
Deal Type : Financing
